2.3. Gal and NGGAs Target AR/AR-V7 and Mnk1/2-eIF4E Signaling Pathways in Drug-Naïve and Drug-Resistant Prostate Cancer Cell Lines. This evidence concerns the gene GAL and prostate carcinoma.